CheckMate-648 expanded these findings to ESCC, with nivolumab plus chemotherapy achieving a median OS of 15.4 months and nivolumab plus ipilimumab achieving 13.7 months, both superior to chemotherapy alone (9.1 months) in PD-L1-expressing tumors [56,57]. This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.